Magaldrate

Magaldrate

Magaldrate

Pharmaceutical drug

Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.

Quick Facts Clinical data, AHFS/Drugs.com ...

Development

Magaldrat was first synthesized by the German chemist Gunther Hallmann and patented on February 2, 1960, by Byk Gulden Lomberg Chemische Fabrik (Germany).[1] In 1983, the active substance was registered as the original drug Riopan.[2]

Available forms

Magaldrate is available in the form of oral suspension or tablets.

Pharmacology

Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly by gastric acid into Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[3]

Interactions and adverse reactions

Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.

References

  1. [1]
    US patent 2923660, Hallmann G, "Process for the preparation of magnesium aluminate hydrate, and therapeutic agents so produced", issued 1960-02-02, assigned to Byk Gulden Lomberg Chem. Fab.
  2. [2]
    Fachinfo Riopan Magen Tabletten, Stand Dezember 2014.
  3. [3]
    Laurence BL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Magaldrate, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.